Clinical Trial Search

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Number of Patients Completing the Protocol — 27 Participants

Primary: Fasting F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging Complete Metabolic Response, Reported Following National Cancer Institute (NCI) and…

Primary: Complete Clinical and Pathologic Response — 50 Percentage of Participants

Primary: Response Rate — .35; .22 proportion of participants

Primary: Number of Participants With Adverse Events — 10 Participants

Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks — -2; -2; -1 change in units on a scale — p=0.08

Primary: Time to Progression (TTP)

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 7; 2 participants

Primary: Change in Serum Estradiol From Baseline to Week 12 — 5.21; 4.46; 5.23; 6.72 pg/ml

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Number of Patients With Dose-limiting Toxicities, as Assessed by CTCAE v 4.0 — 0 Participants

Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants

Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…

Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants

Primary: Persistently Elevated Serum Estradiol Level Outside the Post-menopausal Range — 0; 4 participants

Primary: Percentage of Patients in Remission at 1 Year — 38.1; 38.8 percentage of participants

Primary: Incidence of Dose-limiting Toxicities Treatment-related Adverse Events. — 9; 6 Participants

Primary: Progression-free Survival — 12.89; 8.64 Months

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants

Primary: Time to Progression